GENEVA, Dec 11 (Reuters) - A clinical trial of an Ebola vaccine developed by Merck and NewLink has been halted temporarily as a precautionary measure after four patients complained of joint pains, the University of Geneva Hospital said on Thursday.
"They are all fine and being monitored regularly by the medical team leading the study," it said in a statement.
The human safety trials, which began in Geneva on Nov. 10, are due to resume on Jan. 5 in up to 15 volunteers after checks to ensure that joint pain symptoms in hands and feet were "benign and temporary", the hospital said. Fifty nine volunteers have been vaccinated so far.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.